Brainstorm Cell Therapeutics, Inc. (BCLI)
1.05
-0.02
(-1.87%)
USD |
OTCM |
Sep 04, 16:00
Brainstorm Cell Therapeutics Research and Development Expense (Quarterly) : 0.917M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.917M |
| March 31, 2026 | 0.725M |
| December 31, 2025 | 0.804M |
| September 30, 2025 | 0.851M |
| June 30, 2025 | 1.069M |
| March 31, 2025 | 1.252M |
| December 31, 2024 | 1.67M |
| September 30, 2024 | 0.986M |
| June 30, 2024 | 0.858M |
| March 31, 2024 | 0.897M |
| December 31, 2023 | 1.632M |
| September 30, 2023 | 3.265M |
| June 30, 2023 | 2.727M |
| March 31, 2023 | 2.857M |
| December 31, 2022 | 2.381M |
| September 30, 2022 | 3.706M |
| June 30, 2022 | 5.042M |
| March 31, 2022 | 2.542M |
| December 31, 2021 | 3.607M |
| September 30, 2021 | 3.618M |
| June 30, 2021 | 3.599M |
| March 31, 2021 | 4.341M |
| December 31, 2020 | 8.82M |
| September 30, 2020 | 1.867M |
| June 30, 2020 | 5.694M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.948M |
| December 31, 2019 | 6.186M |
| September 30, 2019 | 4.008M |
| June 30, 2019 | 3.554M |
| March 31, 2019 | 3.456M |
| December 31, 2018 | 3.86M |
| September 30, 2018 | 1.975M |
| June 30, 2018 | 1.481M |
| March 31, 2018 | 0.977M |
| December 31, 2017 | |
| September 30, 2017 | 1.168M |
| June 30, 2017 | 0.435M |
| March 31, 2017 | 0.941M |
| December 31, 2016 | 0.323M |
| September 30, 2016 | 0.79M |
| June 30, 2016 | 0.151M |
| March 31, 2016 | 0.986M |
| December 31, 2015 | 0.826M |
| September 30, 2015 | 1.503M |
| June 30, 2015 | 1.375M |
| March 31, 2015 | 1.245M |
| December 31, 2014 | 1.643M |
| September 30, 2014 | 1.572M |
| June 30, 2014 | 0.877M |
| March 31, 2014 | 0.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| NovelStem International Corp. | -- |
| Summit Therapeutics, Inc. | 157.73M |
| Kezar Life Sciences, Inc. | 1.545M |
| Protara Therapeutics, Inc. | 16.88M |
| Clene, Inc. | 3.135M |